Buja L Maximilian, Fogg Sonya E
Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA -
Houston Academy of Medicine, Texas Medical Center Library, Houston, TX, USA.
Minerva Med. 2025 Aug;116(4):292-299. doi: 10.23736/S0026-4806.25.09660-0. Epub 2025 May 15.
Experimental research sequentially identified reperfusion (in 1972) and conditioning (in 1986) as the two most powerful interventions for reducing acute myocardial infarct (AMI) size following acute coronary occlusion. These discoveries led to further experimental studies on optimal myocardial salvage and intensive clinical efforts to translate these interventions into the management of patients. This umbrella review of systematic reviews addresses the state of research on the effectiveness of pharmacological and interventional conditioning protocols to modulate the impact of ischemia and reperfusion in experimental animals and patients and the comparability of results in experimental animals and humans. This umbrella review documents the paradox of the experimental success of conditioning strategies in the experimental arena and equivocal clinical results of the application of the same conditioning strategies in patients.
The review was conducted using the reporting guideline for overviews of reviews of healthcare interventions codified in the PRIOR statement (https://www.equator-network.org/reporting-guidelines/reporting-guideline-for-overviews-of-reviews-of-healthcare-interventions-development-of-the-prior-statement/).
The results are summarized in the PRISMA format. A discussion is provided of known and unknown factors responsible for the lack of progress in identifying and implementing interventions to further reduce morbidity and mortality from ischemic heart disease, as well as a practical strategy to achieve timely reperfusion in a larger number of patients experiencing acute coronary syndrome.
While awaiting further research to develop a third window of cardioprotection, the most practical approach today is to reduce the morbidity and mortality from IHD is to mount a public education campaign to get the 50% of acute coronary syndrome (ACS) patients with prodromal AMI to the hospital to institute timely reperfusion therapy which has a proven to be the most effective therapy to limit the extend of myocardial damage in patients with IHD. However, the possibility has been raised that the human myocardium may have a genetically determined, primordial non-responsiveness to cardioprotective interventions that exists beyond the established recognized confounding factors. Primordial genetic factors may be particularly difficult to overcome.
实验研究先后确定了再灌注(1972年)和预处理(1986年)是急性冠状动脉闭塞后减少急性心肌梗死(AMI)面积的两种最有效的干预措施。这些发现引发了关于最佳心肌挽救的进一步实验研究,并促使临床进行大量努力,将这些干预措施应用于患者管理。本系统评价的汇总分析探讨了药理学和介入性预处理方案在实验动物和患者中调节缺血和再灌注影响的有效性研究现状,以及实验动物和人类研究结果的可比性。本汇总分析记录了预处理策略在实验领域取得成功与在患者中应用相同预处理策略临床结果不明确之间的矛盾。
结果以PRISMA格式总结。讨论了在识别和实施进一步降低缺血性心脏病发病率和死亡率的干预措施方面缺乏进展的已知和未知因素,以及在更多急性冠状动脉综合征患者中实现及时再灌注的实用策略。
在等待进一步研究以开发第三个心脏保护窗口的同时,目前最实际的方法是通过开展公众教育活动,让50%有前驱AMI的急性冠状动脉综合征(ACS)患者及时就医,接受再灌注治疗,从而降低缺血性心脏病的发病率和死亡率。这已被证明是限制缺血性心脏病患者心肌损伤范围最有效的治疗方法。然而,有人提出,人类心肌可能存在一种由基因决定的、对心脏保护干预的原始无反应性,这种无反应性超出了已公认的混杂因素。原始基因因素可能特别难以克服。